Otonomy Receives $38,500,000 Series B Financing Round

  • Feed Type
  • Date
    8/30/2010
  • Company Name
    Otonomy
  • Mailing Address
    5626 Oberlin Dr. San Diego, CA 92121
  • Company Description
    Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière’s disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus.
  • Website
    http://www.otonomy.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    oceeds from the financing will support Otonomy’s first two programs through pivotal clinical studies as well as expansion of the Company’s pipeline of locally delivered drugs to treat disorders of the ear.
  • M&A Terms
  • Venture Investor
    Novo A/S
  • Venture Investor
    Rivervest Venture Partners
  • Venture Investor
    Domain Associates
  • Venture Investor
    TPG Biotechnology Partners
  • Venture Investor
    Avalon Ventures

By posting a comment, you agree to our terms and conditions.